ORBIMED ADVISORS LLC
Insider CIK 1055951 · TRAW 10% owner · AMBI 10% owner · GKOS Director, 10% owner · ICPT Director, 10% owner · XLRN · SRRA Director, 10% owner · ANTH Director · CCXI 10% owner · AVDR 10% owner · SUPN Director, 10% owner · GNOM 10% owner · PCRX 10% owner · RLYP 10% owner · NONE Director, 10% owner · CNST 10% owner · XTNT Director, 10% owner · SELB Director, 10% owner · SIBN Director · ROKA Director, 10% owner · KALA 10% owner · OTIC Director, 10% owner · ASNS 10% owner · PRNB 10% owner · AFIB Director, 10% owner · SYBX Director · NPCE 10% owner · GRAY 10% owner · SIEN 10% owner · TELA 10% owner · MRTX 10% owner · GH 10% owner · LOXO Director, 10% owner · PIRS Director, 10% owner · DMTX Director, 10% owner · TCDA Director, 10% owner · TPTX Director · VRAY Director, 10% owner · SCPH 10% owner · INSP Director, 10% owner · THOR Director, 10% owner · STDY 10% owner · ADAP Director · ALPN Director, 10% owner · CRVS Director, 10% owner · BOLD Director, 10% owner · AGLE 10% owner · RYTM 10% owner · NTLA Director · ALEC Director, 10% owner · DBTX Director, 10% owner · VRNA Director · NXTC Director, 10% owner · QTTB Director, 10% owner · LOGC Director, 10% owner · KROS Director · SBTX Director, 10% owner · IMRA Director, 10% owner · PRLD Director, 10% owner · STTK Director · ARMO Director, 10% owner · PMVP Director, 10% owner · EWTX Director, 10% owner · PRVL Director, 10% owner · TORC Director, 10% owner · NONE Director, 10% owner · THRX Director, 10% owner · TSBX Director, 10% owner · SWTX 10% owner · MBX Director, 10% owner · ETNB Director, 10% owner · PASG 10% owner · ARQT Director, 10% owner · ORIC Director, 10% owner · KNTE Director, 10% owner · GLTO Director, 10% owner · ADRX Director, 10% owner · FUSN Director · RPTX Director · IRON Director, 10% owner · JANX Director · TERN Director, 10% owner · IKNA Director · BLSM Director · SCTX Director · AVBP Director, 10% owner · NONE Director · THRD Director, 10% owner · UPB Director, 10% owner · SION Director · ETRA Director, 10% owner · BRVE Director, 10% owner · RBM Director, 10% owner · CTIC 10% owner · AMRN Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 2,000,962 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 769,601 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 564,187 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 7,127,019 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 1,333,975 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 513,067 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 10,690,530 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 256,448 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-30 | 588,235 | $17.00 | $10.00M | 588,235 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-30 | 61,516 | $17.00 | $1.05M | 9,292,025 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 10,690,530 | — | $0 | 10,690,530 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 2,000,962 | — | $0 | 12,691,492 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 769,601 | — | $0 | 13,461,093 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 256,448 | — | $0 | 9,230,509 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 513,067 | — | $0 | 8,974,061 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 1,333,975 | — | $0 | 8,460,994 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 7,127,019 | — | $0 | 7,127,019 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-30 | 300,249 | $17.00 | $5.10M | 14,325,529 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 564,187 | — | $0 | 14,025,280 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 256,448 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 513,067 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 1,333,975 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 7,127,019 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 564,187 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 769,601 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 2,000,962 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 10,690,530 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-30 | 588,235 | $17.00 | $10.00M | 588,235 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-30 | 61,516 | $17.00 | $1.05M | 9,292,025 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 256,448 | — | — | 9,230,509 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 513,067 | — | — | 8,974,061 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 1,333,975 | — | — | 8,460,994 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 7,127,019 | — | — | 7,127,019 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-30 | 300,249 | $17.00 | $5.10M | 14,325,529 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 564,187 | — | — | 14,025,280 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 769,601 | — | — | 13,461,093 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 2,000,962 | — | — | 12,691,492 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 10,690,530 | — | — | 10,690,530 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion deriv | 2026-09-21 | 2026-09-23 | 2,002,310 | — | $0 | 0 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion deriv | 2026-09-21 | 2026-09-23 | 758,279 | — | $0 | 0 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion deriv | 2026-09-21 | 2026-09-23 | 1,703,314 | — | $0 | 0 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion deriv | 2026-09-21 | 2026-09-23 | 1,087,934 | — | $0 | 0 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | P Buy | 2026-09-21 | 2026-09-23 | 333,333 | $15.00 | $5.00M | 5,126,891 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion | 2026-09-21 | 2026-09-23 | 1,087,934 | — | $0 | 3,090,244 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | P Buy | 2026-09-21 | 2026-09-23 | 1,000,000 | $15.00 | $15.00M | 1,758,279 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion | 2026-09-21 | 2026-09-23 | 758,279 | — | $0 | 758,279 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion | 2026-09-21 | 2026-09-23 | 1,703,314 | — | $0 | 4,793,558 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion | 2026-09-21 | 2026-09-23 | 2,002,310 | — | $0 | 2,002,310 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion deriv | 2026-09-21 | 2026-09-23 | 758,279 | — | $0 | 0 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion deriv | 2026-09-21 | 2026-09-23 | 1,703,314 | — | $0 | 0 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion deriv | 2026-09-21 | 2026-09-23 | 1,087,934 | — | $0 | 0 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion deriv | 2026-09-21 | 2026-09-23 | 2,002,310 | — | $0 | 0 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | P Buy | 2026-09-21 | 2026-09-23 | 1,000,000 | $15.00 | $15.00M | 1,758,279 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion | 2026-09-21 | 2026-09-23 | 758,279 | — | — | 758,279 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | P Buy | 2026-09-21 | 2026-09-23 | 333,333 | $15.00 | $5.00M | 5,126,891 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion | 2026-09-21 | 2026-09-23 | 1,703,314 | — | — | 4,793,558 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion | 2026-09-21 | 2026-09-23 | 1,087,934 | — | — | 3,090,244 | SEC↗ |
| ETRA Electra Therapeutics, Inc. | C Conversion | 2026-09-21 | 2026-09-23 | 2,002,310 | — | — | 2,002,310 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion deriv | 2026-08-10 | 2026-08-12 | 1,049,283 | — | $0 | 0 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion deriv | 2026-08-10 | 2026-08-12 | 1,039,996 | — | $0 | 0 | SEC↗ |
| BLSM BlossomHill Therapeutics, | P Buy | 2026-08-10 | 2026-08-12 | 625,000 | $16.00 | $10.00M | 2,714,279 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion | 2026-08-10 | 2026-08-12 | 1,049,283 | — | $0 | 2,089,279 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion | 2026-08-10 | 2026-08-12 | 1,039,996 | — | $0 | 1,039,996 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion deriv | 2026-08-10 | 2026-08-12 | 1,049,283 | — | $0 | 0 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion deriv | 2026-08-10 | 2026-08-12 | 1,039,996 | — | $0 | 0 | SEC↗ |
| BLSM BlossomHill Therapeutics, | P Buy | 2026-08-10 | 2026-08-12 | 625,000 | $16.00 | $10.00M | 2,714,279 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion | 2026-08-10 | 2026-08-12 | 1,049,283 | — | — | 2,089,279 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion | 2026-08-10 | 2026-08-12 | 1,039,996 | — | — | 1,039,996 | SEC↗ |
| BRVE Braveheart Bio, Inc. | C Conversion deriv | 2026-08-07 | 2026-08-11 | 40,000,000 | — | $0 | 0 | SEC↗ |
| BRVE Braveheart Bio, Inc. | P Buy | 2026-08-07 | 2026-08-11 | 273,333 | $18.00 | $4.92M | 273,333 | SEC↗ |
| BRVE Braveheart Bio, Inc. | C Conversion | 2026-08-07 | 2026-08-11 | 9,132,420 | — | $0 | 10,235,159 | SEC↗ |
| BRVE Braveheart Bio, Inc. | P Buy | 2026-08-07 | 2026-08-11 | 1,666,667 | $18.00 | $30.00M | 11,901,826 | SEC↗ |
| BRVE Braveheart Bio, Inc. | C Conversion deriv | 2026-08-07 | 2026-08-11 | 40,000,000 | — | $0 | 0 | SEC↗ |
| BRVE Braveheart Bio, Inc. | P Buy | 2026-08-07 | 2026-08-11 | 273,333 | $18.00 | $4.92M | 273,333 | SEC↗ |
| BRVE Braveheart Bio, Inc. | P Buy | 2026-08-07 | 2026-08-11 | 1,666,667 | $18.00 | $30.00M | 11,901,826 | SEC↗ |
| BRVE Braveheart Bio, Inc. | C Conversion | 2026-08-07 | 2026-08-11 | 9,132,420 | — | — | 10,235,159 | SEC↗ |
| SCTX Scribe Therapeutics, Inc. | C Conversion deriv | 2026-07-27 | 2026-07-29 | 2,065,672 | — | $0 | 0 | SEC↗ |
| SCTX Scribe Therapeutics, Inc. | C Conversion | 2026-07-27 | 2026-07-29 | 348,825 | — | $0 | 348,825 | SEC↗ |
| SCTX Scribe Therapeutics, Inc. | P Buy | 2026-07-27 | 2026-07-29 | 1,000,000 | $15.00 | $15.00M | 1,348,825 | SEC↗ |
| SCTX Scribe Therapeutics, Inc. | C Conversion deriv | 2026-07-27 | 2026-07-29 | 2,065,672 | — | $0 | 0 | SEC↗ |
| SCTX Scribe Therapeutics, Inc. | P Buy | 2026-07-27 | 2026-07-29 | 1,000,000 | $15.00 | $15.00M | 1,348,825 | SEC↗ |
| SCTX Scribe Therapeutics, Inc. | C Conversion | 2026-07-27 | 2026-07-29 | 348,825 | — | — | 348,825 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-07-07 | 2026-07-09 | 85,918 | $44.86 | $3.85M | 2,469,959 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-06-30 | 2026-07-02 | 115,844 | $45.50 | $5.27M | 2,555,877 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-06-22 | 2026-06-24 | 1,477 | $45.00 | $66.5K | 219,405 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-06-22 | 2026-06-24 | 787,024 | $45.38 | $35.72M | 6,601,878 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-06-22 | 2026-06-24 | 46,776 | $45.00 | $2.10M | 6,555,102 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-06-22 | 2026-06-24 | 24,846 | $45.38 | $1.13M | 220,882 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-06-15 | 2026-06-17 | 272,322 | $45.02 | $12.26M | 7,388,902 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-06-15 | 2026-06-17 | 9,086 | $45.02 | $409.1K | 245,728 | SEC↗ |
| STTK Shattuck Labs, Inc. | P Buy deriv | 2026-06-11 | 2026-06-15 | 208,333 | — | $0 | 5,303,908 | SEC↗ |
| STTK Shattuck Labs, Inc. | P Buy deriv | 2026-06-11 | 2026-06-15 | 1,041,667 | — | $0 | 26,519,541 | SEC↗ |
| STTK Shattuck Labs, Inc. | C Conversion deriv | 2026-06-08 | 2026-06-09 | 15,366,490 | — | $0 | 25,477,874 | SEC↗ |
| STTK Shattuck Labs, Inc. | C Conversion deriv | 2026-06-08 | 2026-06-09 | 3,073,298 | — | $0 | 5,095,575 | SEC↗ |
| STTK Shattuck Labs, Inc. | C Conversion deriv | 2026-06-08 | 2026-06-09 | 15,366,490 | — | $0 | 0 | SEC↗ |
| STTK Shattuck Labs, Inc. | C Conversion deriv | 2026-06-08 | 2026-06-09 | 3,073,298 | — | $0 | 0 | SEC↗ |
| QTTB Q32 Bio Inc. | P Buy | 2026-05-28 | 2026-06-01 | 1,250,000 | $8.00 | $10.00M | 3,502,987 | SEC↗ |
| QTTB Q32 Bio Inc. | P Buy | 2026-05-28 | 2026-06-01 | 625,000 | $8.00 | $5.00M | 625,000 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-05-27 | 2026-05-29 | 101 | $44.49 | $4.5K | 2,671,721 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-05-11 | 2026-05-11 | 184,639 | $46.22 | $8.53M | 2,671,822 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-05-08 | 2026-05-11 | 59,767 | $44.58 | $2.66M | 2,856,461 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-05-07 | 2026-05-11 | 48,546 | $44.61 | $2.17M | 2,916,228 | SEC↗ |
| PRLD Prelude Therapeutics Inc | P Buy | 2026-04-21 | 2026-04-23 | 1,126,126 | $4.44 | $5.00M | 1,126,126 | SEC↗ |
| PRLD Prelude Therapeutics Inc | P Buy | 2026-04-21 | 2026-04-23 | 1,689,189 | $4.44 | $7.50M | 11,808,945 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-04-18 | 2026-04-21 | 2,948 | $44.52 | $131.2K | 2,964,774 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-04-17 | 2026-04-21 | 52,397 | $44.68 | $2.34M | 2,967,722 | SEC↗ |
| TRAW Traws Pharma, Inc. | P Buy deriv | 2026-04-16 | 2026-04-28 | 597,729 | — | $0 | 597,729 | SEC↗ |
| TRAW Traws Pharma, Inc. | P Buy deriv | 2026-04-16 | 2026-04-28 | 597,729 | — | $0 | 597,729 | SEC↗ |
| TRAW Traws Pharma, Inc. | P Buy deriv | 2026-04-16 | 2026-04-28 | 1,793,187 | — | $0 | 1,793,187 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-04-16 | 2026-04-16 | 226,906 | $45.34 | $10.29M | 3,020,119 | SEC↗ |
| TRAW Traws Pharma, Inc. | P Buy | 2026-04-16 | 2026-04-28 | 597,729 | $1.67 | $998.2K | 1,203,250 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-04-15 | 2026-04-16 | 235,863 | $44.64 | $10.53M | 3,247,025 | SEC↗ |
| IMA ImageneBio, Inc. | P Buy deriv | 2026-04-14 | 2026-04-16 | 336,603 | — | $0 | 336,603 | SEC↗ |
| IMA ImageneBio, Inc. | P Buy deriv | 2026-04-14 | 2026-04-16 | 384,689 | — | $0 | 384,689 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-04-14 | 2026-04-16 | 47,814 | $44.51 | $2.13M | 3,482,888 | SEC↗ |
| ACET Adicet Bio, Inc. | S Sale | 2026-04-08 | 2026-04-09 | 40,416 | $6.52 | $263.5K | 0 | SEC↗ |
| ACET Adicet Bio, Inc. | S Sale | 2026-04-08 | 2026-04-09 | 32,523 | $6.29 | $204.6K | 0 | SEC↗ |
| ACET Adicet Bio, Inc. | S Sale | 2026-04-07 | 2026-04-09 | 2,400 | $6.38 | $15.3K | 32,523 | SEC↗ |
| ACET Adicet Bio, Inc. | S Sale | 2026-04-07 | 2026-04-09 | 29,319 | $6.53 | $191.5K | 34,923 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-02-03 | 2026-02-04 | 29,063 | $44.58 | $1.30M | 3,530,702 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-02-02 | 2026-02-04 | 1,890 | $44.57 | $84.2K | 3,559,765 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-12-24 | 2025-12-29 | 33,356 | $44.55 | $1.49M | 3,561,655 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-12-19 | 2025-12-19 | 875 | $44.49 | $38.9K | 3,595,011 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-12-18 | 2025-12-19 | 100 | $44.49 | $4.4K | 3,595,886 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-12-17 | 2025-12-19 | 900 | $44.50 | $40.0K | 3,595,986 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-11-26 | 2025-11-26 | 1,600 | $44.49 | $71.2K | 3,596,886 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-11-25 | 2025-11-26 | 11,890 | $44.60 | $530.3K | 3,598,486 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-11-24 | 2025-11-26 | 94,583 | $44.54 | $4.21M | 3,610,376 | SEC↗ |
| KROS Keros Therapeutics, Inc. | D To issuer | 2025-11-21 | 2025-12-18 | 74,465 | $17.75 | $1.32M | 45,057 | SEC↗ |
| KROS Keros Therapeutics, Inc. | D To issuer | 2025-11-21 | 2025-12-18 | 140,057 | $17.75 | $2.49M | 759,155 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | S Sale | 2025-10-23 | 2025-10-27 | 1,000,000 | $1.52 | $1.52M | 4,975,291 | SEC↗ |
| ACET Adicet Bio, Inc. | P Buy | 2025-10-08 | 2025-10-10 | 3,500,000 | $1.00 | $3.50M | 4,490,254 | SEC↗ |
| ACET Adicet Bio, Inc. | P Buy | 2025-10-08 | 2025-10-10 | 1,500,000 | $1.00 | $1.50M | 9,026,359 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | S Sale | 2025-09-10 | 2025-09-12 | 500,000 | $1.80 | $900.0K | 5,975,291 | SEC↗ |
| STTK Shattuck Labs, Inc. | P Buy deriv | 2025-08-25 | 2025-09-02 | 15,366,490 | — | $0 | 15,366,490 | SEC↗ |
| STTK Shattuck Labs, Inc. | P Buy deriv | 2025-08-25 | 2025-09-02 | 3,073,298 | — | $0 | 3,073,298 | SEC↗ |
| STTK Shattuck Labs, Inc. | P Buy deriv | 2025-08-25 | 2025-09-02 | 10,111,384 | — | $0 | 10,111,384 | SEC↗ |
| STTK Shattuck Labs, Inc. | P Buy deriv | 2025-08-25 | 2025-09-02 | 2,022,277 | — | $0 | 2,022,277 | SEC↗ |
| STTK Shattuck Labs, Inc. | P Buy | 2025-08-25 | 2025-09-02 | 1,051,021 | $0.87 | $914.4K | 1,051,021 | SEC↗ |
| STTK Shattuck Labs, Inc. | P Buy | 2025-08-25 | 2025-09-02 | 5,255,106 | $0.87 | $4.57M | 5,255,106 | SEC↗ |
| TSBX Turnstone Biologics Corp. | U Tender | 2025-08-08 | 2025-08-12 | 3,099,265 | — | $0 | 0 | SEC↗ |
| IKNA ImageneBio, Inc. | A Award | 2025-07-25 | 2025-07-30 | 83,611 | $2.49 | $208.2K | 287,885 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | X Exercise deriv | 2025-06-27 | 2025-07-01 | 1,397,684 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | X Exercise | 2025-06-27 | 2025-07-01 | 1,397,684 | $3.50 | $4.89M | 8,341,338 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | S Sale | 2025-06-27 | 2025-07-01 | 1,176,332 | $4.16 | $4.89M | 7,165,006 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-06-26 | 2025-06-26 | 213,257 | $0.33 | $70.4K | 6,066,343 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-06-25 | 2025-06-26 | 138,800 | $0.33 | $45.8K | 6,279,600 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-06-24 | 2025-06-26 | 231,600 | $0.35 | $81.1K | 6,418,400 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2025-05-14 | 2025-05-16 | 134,136 | $15.83 | $2.12M | 3,272,199 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2025-05-14 | 2025-05-16 | 34,000 | $15.94 | $542.0K | 3,238,199 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-04-24 | 2025-04-24 | 68,195 | $0.32 | $21.8K | 6,650,000 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-04-23 | 2025-04-24 | 89,328 | $0.34 | $30.4K | 6,718,195 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-04-22 | 2025-04-24 | 78,049 | $0.34 | $26.5K | 6,807,523 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-04-17 | 2025-04-17 | 77,090 | $0.33 | $25.4K | 6,885,572 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-04-16 | 2025-04-17 | 61,638 | $0.33 | $20.3K | 6,962,662 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-04-15 | 2025-04-17 | 10,326 | $0.38 | $3.9K | 7,024,300 | SEC↗ |
| XTNT Xtant Medical Holdings, In | S Sale | 2025-04-10 | 2025-04-14 | 56,004,974 | $0.42 | $23.52M | 0 | SEC↗ |
| XTNT Xtant Medical Holdings, In | S Sale | 2025-04-10 | 2025-04-14 | 17,109,618 | $0.42 | $7.19M | 0 | SEC↗ |
| CMPX Compass Therapeutics, Inc. | S Sale | 2025-04-09 | 2025-04-11 | 3,571,428 | $1.59 | $5.68M | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2025-04-03 | 2025-04-04 | 372,578 | $20.13 | $7.50M | 14,809,075 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2025-04-03 | 2025-04-04 | 124,193 | $20.13 | $2.50M | 443,792 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-24 | 2025-03-26 | 1,956 | $54.11 | $105.8K | 482,308 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-24 | 2025-03-26 | 3,026 | $54.11 | $163.7K | 746,171 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-24 | 2025-03-26 | 756 | $54.11 | $40.9K | 186,541 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-21 | 2025-03-21 | 1,320 | $54.00 | $71.3K | 187,297 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-21 | 2025-03-21 | 5,279 | $54.00 | $285.1K | 749,197 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-21 | 2025-03-21 | 3,412 | $54.00 | $184.2K | 484,264 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-20 | 2025-03-21 | 364 | $54.01 | $19.7K | 188,617 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-20 | 2025-03-21 | 1,457 | $54.01 | $78.7K | 754,476 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-20 | 2025-03-21 | 941 | $54.01 | $50.8K | 487,676 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-19 | 2025-03-21 | 5,228 | $54.02 | $282.4K | 188,981 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-19 | 2025-03-21 | 20,911 | $54.02 | $1.13M | 755,933 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-19 | 2025-03-21 | 13,517 | $54.02 | $730.2K | 488,617 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-12 | 2025-03-12 | 10,733 | $54.44 | $584.3K | 194,209 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-12 | 2025-03-12 | 603 | $55.05 | $33.2K | 529,884 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-12 | 2025-03-12 | 933 | $55.05 | $51.4K | 819,774 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-12 | 2025-03-12 | 233 | $55.05 | $12.8K | 204,942 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-12 | 2025-03-12 | 42,930 | $54.44 | $2.34M | 776,844 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-12 | 2025-03-12 | 27,750 | $54.44 | $1.51M | 502,134 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-11 | 2025-03-12 | 9,222 | $54.01 | $498.1K | 530,487 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-11 | 2025-03-12 | 14,267 | $54.01 | $770.6K | 820,707 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-11 | 2025-03-12 | 3,567 | $54.01 | $192.7K | 205,175 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-10 | 2025-03-12 | 68,766 | $54.29 | $3.73M | 539,845 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-10 | 2025-03-12 | 106,384 | $54.29 | $5.78M | 835,185 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-10 | 2025-03-12 | 26,596 | $54.29 | $1.44M | 208,795 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-10 | 2025-03-12 | 136 | $55.01 | $7.5K | 539,709 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-10 | 2025-03-12 | 211 | $55.01 | $11.6K | 834,974 | SEC↗ |
| IRON Disc Medicine, Inc. | S Sale | 2025-03-10 | 2025-03-12 | 53 | $55.01 | $2.9K | 208,742 | SEC↗ |
| MBX MBX Biosciences, Inc. | P Buy | 2025-02-18 | 2025-02-19 | 49,070 | $10.84 | $531.9K | 3,255,000 | SEC↗ |
| MBX MBX Biosciences, Inc. | P Buy | 2025-02-18 | 2025-02-19 | 94,100 | $10.84 | $1.02M | 747,887 | SEC↗ |
| MBX MBX Biosciences, Inc. | P Buy | 2025-02-14 | 2025-02-19 | 29,540 | $9.85 | $291.0K | 3,205,930 | SEC↗ |
| MBX MBX Biosciences, Inc. | P Buy | 2025-02-14 | 2025-02-19 | 17,962 | $9.90 | $177.8K | 3,176,390 | SEC↗ |
| SION Sionna Therapeutics, Inc. | C Conversion deriv | 2025-02-10 | 2025-02-10 | 2,560,951 | — | $0 | 0 | SEC↗ |
| SION Sionna Therapeutics, Inc. | C Conversion deriv | 2025-02-10 | 2025-02-10 | 2,048,760 | — | $0 | 0 | SEC↗ |
| SION Sionna Therapeutics, Inc. | P Buy | 2025-02-10 | 2025-02-10 | 550,000 | $18.00 | $9.90M | 3,704,959 | SEC↗ |
| SION Sionna Therapeutics, Inc. | C Conversion | 2025-02-10 | 2025-02-10 | 3,154,959 | — | $0 | 3,154,959 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-01-14 | 2025-01-14 | 79,024 | $0.60 | $47.4K | 7,034,626 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-01-13 | 2025-01-14 | 17,986 | $0.64 | $11.5K | 7,113,650 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-01-10 | 2025-01-14 | 126,209 | $0.66 | $83.3K | 7,131,636 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-01-08 | 2025-01-08 | 75,007 | $0.68 | $51.0K | 7,257,845 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-01-07 | 2025-01-08 | 52,536 | $0.71 | $37.3K | 7,332,852 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2025-01-06 | 2025-01-08 | 19,481 | $0.77 | $15.0K | 7,385,388 | SEC↗ |
| TRAW Traws Pharma, Inc. | P Buy deriv | 2024-12-29 | 2025-01-27 | 96,348 | — | $0 | 96,348 | SEC↗ |
| TRAW Traws Pharma, Inc. | P Buy deriv | 2024-12-29 | 2025-01-27 | 96,348 | — | $0 | 96,348 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2024-12-20 | 2024-12-26 | 230,321 | $0.60 | $138.2K | 7,404,869 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2024-12-11 | 2024-12-11 | 80 | $0.80 | $64 | 7,635,190 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2024-12-10 | 2024-12-11 | 8,015 | $0.80 | $6.4K | 7,635,270 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2024-12-09 | 2024-12-11 | 54,181 | $0.84 | $45.5K | 7,643,285 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2024-12-06 | 2024-12-06 | 20,903 | $0.82 | $17.1K | 7,697,466 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2024-12-04 | 2024-12-06 | 76,200 | $0.79 | $60.2K | 7,718,369 | SEC↗ |
| NONE Lomond Therapeutics Holdin | C Conversion deriv | 2024-11-01 | 2024-11-05 | 215,146 | — | $0 | 0 | SEC↗ |
| NONE Lomond Therapeutics Holdin | C Conversion deriv | 2024-11-01 | 2024-11-05 | 389,078 | — | $0 | 0 | SEC↗ |
| NONE Lomond Therapeutics Holdin | C Conversion deriv | 2024-11-01 | 2024-11-05 | 230,753 | — | $0 | 0 | SEC↗ |
| NONE Lomond Therapeutics Holdin | C Conversion deriv | 2024-11-01 | 2024-11-05 | 74,613 | — | $0 | 0 | SEC↗ |
| NONE Lomond Therapeutics Holdin | C Conversion deriv | 2024-11-01 | 2024-11-05 | 323,916 | — | $0 | 0 | SEC↗ |
| NONE Lomond Therapeutics Holdin | C Conversion | 2024-11-01 | 2024-11-05 | 215,146 | $3.20 | $688.5K | 539,062 | SEC↗ |
| NONE Lomond Therapeutics Holdin | C Conversion | 2024-11-01 | 2024-11-05 | 230,753 | $3.60 | $830.7K | 1,158,893 | SEC↗ |
| NONE Lomond Therapeutics Holdin | C Conversion | 2024-11-01 | 2024-11-05 | 74,613 | $3.60 | $268.6K | 1,233,506 | SEC↗ |
| NONE Lomond Therapeutics Holdin | A Award | 2024-11-01 | 2024-11-05 | 808,894 | $4.00 | $3.24M | 2,042,400 | SEC↗ |
| NONE Lomond Therapeutics Holdin | A Award | 2024-11-01 | 2024-11-05 | 479,736 | $4.00 | $1.92M | 2,522,136 | SEC↗ |
| NONE Lomond Therapeutics Holdin | A Award | 2024-11-01 | 2024-11-05 | 155,120 | $4.00 | $620.5K | 2,677,256 | SEC↗ |
| NONE Lomond Therapeutics Holdin | C Conversion | 2024-11-01 | 2024-11-05 | 389,078 | $3.60 | $1.40M | 928,140 | SEC↗ |
| NONE Lomond Therapeutics Holdin | C Conversion | 2024-11-01 | 2024-11-05 | 323,916 | $3.20 | $1.04M | 323,916 | SEC↗ |
| UPB Upstream Bio, Inc. | C Conversion deriv | 2024-10-15 | 2024-10-17 | 524,500 | — | $0 | 0 | SEC↗ |
| UPB Upstream Bio, Inc. | C Conversion deriv | 2024-10-15 | 2024-10-17 | 2,098,000 | — | $0 | 0 | SEC↗ |
| UPB Upstream Bio, Inc. | C Conversion deriv | 2024-10-15 | 2024-10-17 | 197,456 | — | $0 | 0 | SEC↗ |
| UPB Upstream Bio, Inc. | C Conversion deriv | 2024-10-15 | 2024-10-17 | 789,833 | — | $0 | 0 | SEC↗ |
| UPB Upstream Bio, Inc. | P Buy | 2024-10-15 | 2024-10-17 | 660,000 | $17.00 | $11.22M | 4,554,873 | SEC↗ |
| UPB Upstream Bio, Inc. | C Conversion | 2024-10-15 | 2024-10-17 | 721,956 | — | $0 | 973,716 | SEC↗ |
| UPB Upstream Bio, Inc. | P Buy | 2024-10-15 | 2024-10-17 | 165,000 | $17.00 | $2.81M | 1,138,716 | SEC↗ |
| UPB Upstream Bio, Inc. | C Conversion | 2024-10-15 | 2024-10-17 | 2,887,833 | — | $0 | 3,894,873 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2024-09-19 | 2024-09-23 | 39,300 | $0.71 | $27.9K | 7,794,569 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2024-09-18 | 2024-09-18 | 25,631 | $0.73 | $18.7K | 7,833,869 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2024-09-17 | 2024-09-18 | 111,400 | $0.73 | $81.3K | 7,859,500 | SEC↗ |
| MBX MBX Biosciences, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 4,854,368 | — | $0 | 0 | SEC↗ |
| MBX MBX Biosciences, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 19,587,284 | — | $0 | 0 | SEC↗ |
| MBX MBX Biosciences, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 12,372,634 | — | $0 | 0 | SEC↗ |
| MBX MBX Biosciences, Inc. | P Buy | 2024-09-16 | 2024-09-17 | 250,000 | $16.00 | $4.00M | 653,787 | SEC↗ |
| MBX MBX Biosciences, Inc. | C Conversion | 2024-09-16 | 2024-09-17 | 403,787 | — | $0 | 403,787 | SEC↗ |
| MBX MBX Biosciences, Inc. | P Buy | 2024-09-16 | 2024-09-17 | 500,000 | $16.00 | $8.00M | 3,158,428 | SEC↗ |
| MBX MBX Biosciences, Inc. | C Conversion | 2024-09-16 | 2024-09-17 | 2,658,428 | — | $0 | 2,658,428 | SEC↗ |
| PASG Passage BIO, Inc. | S Sale | 2024-09-16 | 2024-09-18 | 63,100 | $0.74 | $46.7K | 7,970,900 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-08-26 | 2024-08-28 | 83,695 | $13.00 | $1.09M | 0 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-08-23 | 2024-08-23 | 69,500 | $13.03 | $905.6K | 83,695 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-08-22 | 2024-08-23 | 391,482 | $12.94 | $5.07M | 153,195 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-08-21 | 2024-08-23 | 13,300 | $14.61 | $194.3K | 544,677 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-08-21 | 2024-08-23 | 394,400 | $13.52 | $5.33M | 557,977 | SEC↗ |
| SCPH scPharmaceuticals Inc. | P Buy | 2024-08-13 | 2024-08-15 | 478,342 | $4.00 | $1.91M | 5,806,670 | SEC↗ |
| SCPH scPharmaceuticals Inc. | P Buy | 2024-08-13 | 2024-08-15 | 21,658 | $4.00 | $86.6K | 252,858 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2024-08-13 | 2024-08-15 | 220,600 | $44.01 | $9.71M | 899,212 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2024-08-13 | 2024-08-15 | 29,400 | $44.01 | $1.29M | 119,522 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | S Sale | 2024-07-16 | 2024-07-17 | 556 | $10.00 | $5.6K | 1,967,924 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | S Sale | 2024-07-16 | 2024-07-17 | 4,009 | $10.00 | $40.1K | 4,839,412 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | S Sale | 2024-07-16 | 2024-07-17 | 623 | $10.00 | $6.2K | 755,635 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | S Sale | 2024-07-15 | 2024-07-17 | 39,433 | $10.00 | $394.3K | 4,843,421 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | S Sale | 2024-07-15 | 2024-07-17 | 5,401 | $10.00 | $54.0K | 1,968,480 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | S Sale | 2024-07-15 | 2024-07-17 | 6,142 | $10.00 | $61.4K | 756,258 | SEC↗ |
| TELA TELA Bio, Inc. | S Sale | 2024-07-02 | 2024-07-02 | 36,600 | $4.54 | $166.2K | 2,407,242 | SEC↗ |
| TELA TELA Bio, Inc. | S Sale | 2024-07-01 | 2024-07-02 | 13,700 | $4.68 | $64.1K | 2,443,842 | SEC↗ |
| TELA TELA Bio, Inc. | S Sale | 2024-06-28 | 2024-07-02 | 378,000 | $4.74 | $1.79M | 2,457,542 | SEC↗ |
| IRON Disc Medicine, Inc. | P Buy | 2024-06-17 | 2024-06-20 | 43,944 | $36.00 | $1.58M | 941,569 | SEC↗ |
| IRON Disc Medicine, Inc. | P Buy | 2024-06-17 | 2024-06-20 | 10,986 | $36.00 | $395.5K | 235,391 | SEC↗ |
| IRON Disc Medicine, Inc. | P Buy | 2024-06-17 | 2024-06-20 | 28,404 | $36.00 | $1.02M | 608,611 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | U Tender | 2024-05-18 | 2024-05-20 | 264,315 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | U Tender | 2024-05-18 | 2024-05-20 | 2,416,181 | — | $0 | 0 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-05-16 | 2024-05-20 | 1,000,000 | $22.14 | $22.14M | 7,663,349 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-05-16 | 2024-05-20 | 33,300 | $22.14 | $737.3K | 254,814 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy deriv | 2024-05-06 | 2024-05-08 | 1,444,085 | $1.73 | $2.50M | 1,444,085 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy deriv | 2024-05-06 | 2024-05-08 | 1,397,684 | — | $0 | 1,397,684 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2024-05-03 | 2024-05-03 | 4,674 | $14.03 | $65.6K | 3,406,335 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2024-05-02 | 2024-05-03 | 8,842 | $14.01 | $123.9K | 3,411,009 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2024-05-01 | 2024-05-03 | 15,690 | $14.02 | $220.0K | 3,419,851 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2024-04-24 | 2024-04-26 | 1,781 | $14.06 | $25.0K | 3,435,541 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2024-04-23 | 2024-04-23 | 21,791 | $14.29 | $311.4K | 3,437,322 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2024-04-22 | 2024-04-23 | 24,609 | $14.05 | $345.8K | 3,459,113 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2024-04-19 | 2024-04-23 | 18,253 | $14.02 | $255.9K | 3,483,722 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2024-04-18 | 2024-04-18 | 2,623 | $14.06 | $36.9K | 3,501,975 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2024-04-17 | 2024-04-18 | 300 | $14.15 | $4.2K | 3,504,598 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2024-04-16 | 2024-04-18 | 14,069 | $14.01 | $197.1K | 3,504,898 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2024-04-12 | 2024-04-15 | 23,101 | $14.42 | $333.1K | 3,518,967 | SEC↗ |
| NPCE NeuroPace Inc | S Sale | 2024-04-11 | 2024-04-15 | 461,899 | $14.49 | $6.69M | 3,542,068 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | D To issuer | 2024-04-03 | 2024-04-05 | 84,599 | — | $0 | 0 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | D To issuer | 2024-04-03 | 2024-04-05 | 450,000 | — | $0 | 0 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | D To issuer | 2024-04-03 | 2024-04-05 | 1,368,338 | — | $0 | 0 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | D To issuer | 2024-04-03 | 2024-04-05 | 1,368,339 | — | $0 | 0 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | D To issuer | 2024-04-03 | 2024-04-05 | 4,738,453 | — | $0 | 0 | SEC↗ |
| THRX Theseus Pharmaceuticals, I | U Tender | 2024-02-14 | 2024-02-14 | 17,063,000 | — | $0 | 0 | SEC↗ |
| THRX Theseus Pharmaceuticals, I | U Tender | 2024-02-14 | 2024-02-14 | 650,600 | — | $0 | 0 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | C Conversion deriv | 2024-01-30 | 2024-01-31 | 469,615 | — | $0 | 0 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | C Conversion deriv | 2024-01-30 | 2024-01-31 | 469,615 | — | $0 | 0 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | C Conversion deriv | 2024-01-30 | 2024-01-31 | 821,827 | — | $0 | 0 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | C Conversion deriv | 2024-01-30 | 2024-01-31 | 821,827 | — | $0 | 0 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | C Conversion | 2024-01-30 | 2024-01-31 | 821,827 | — | $0 | 821,827 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | C Conversion | 2024-01-30 | 2024-01-31 | 821,827 | — | $0 | 821,827 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | C Conversion | 2024-01-30 | 2024-01-31 | 469,615 | — | $0 | 1,291,442 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | C Conversion | 2024-01-30 | 2024-01-31 | 469,615 | — | $0 | 1,291,442 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | P Buy | 2024-01-30 | 2024-01-31 | 222,222 | $18.00 | $4.00M | 1,513,664 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | P Buy | 2024-01-30 | 2024-01-31 | 222,222 | $18.00 | $4.00M | 1,513,664 | SEC↗ |
| ACET Adicet Bio, Inc. | P Buy | 2024-01-25 | 2024-01-26 | 1,841,100 | $2.40 | $4.42M | 7,526,359 | SEC↗ |
| ACET Adicet Bio, Inc. | P Buy | 2024-01-25 | 2024-01-26 | 1,041,700 | $2.40 | $2.50M | 1,255,985 | SEC↗ |